US2007031476A1PendingUtilityA1

Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)

33
Assignee: TALLBERG THOMASPriority: Oct 17, 2003Filed: Oct 15, 2004Published: Feb 8, 2007
Est. expiryOct 17, 2023(expired)· nominal 20-yr term from priority
Inventors:Thomas Tallberg
A61P 35/00A61P 35/04A61K 31/198A61P 3/02A61K 33/24
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the treatment and prophylaxis of cancer. In particular, the invention relates to a pharmaceutical agent comprising strontium, amino acid(s) and mineral element(s), and its use in the preparation of an agent useful for the treatment and prophylaxis of cancer. The invention also relates to a method for treatment and prophylaxis of cancer.

Claims

exact text as granted — not AI-modified
1 . Pharmaceutical agent for the treatment or prophylaxis of cancer, characterized in that it consists essentially of strontium, at least one amino acid selected from the group consisting of arginine, serine, asparagine, glycine, glutamine, lysine, at least one mineral element selected from the group consisting of chromium, tin, vanadium and wolfram, and vitamins.  
   
   
       2 . Pharmaceutical agent according to  claim 1 , characterized in that strontium is present in the form of strontium ions.  
   
   
       3 . Pharmaceutical agent according to  claim 1 , characterized in that strontium is present in the form of strontium chloride or strontium oxide.  
   
   
       4 . Pharmaceutical agent according to  claim 1 , characterized in that it comprises 0.1-3 mg strontium, at least one L amino acid selected from the group consisting of arginine, serine, asparagine, glycine, glutamine, lysine, in an amount of 2-5 g of each of the chosen amino acids, at least one mineral element selected from the group consisting of chromium, tin, vanadium and wolfram, in an amount of 1-3 mg of each of the chosen mineral elements, the amounts being calculated as daily intake.  
   
   
       5 . Pharmaceutical agent according to  claim 1 , characterized in that it comprises strontium, serine and vanadium.  
   
   
       6 . Pharmaceutical agent according to  claim 1 , characterized in that it comprises arginine and vanadium.  
   
   
       7 . Pharmaceutical agent according to  claim 1 , characterized in that it comprises strontium and isoleucin and at least one mineral element selected from the group consisting of chromium, tin, vanadium, selenium, and wolfram.  
   
   
       8 . Pharmaceutical agent according to  claim 1 , characterized in that it is in the form of a food additive or a food ingredient.  
   
   
       9 . Pharmaceutical agent according to  claim 8 , characterized in that it is in the form of a dairy product, preferably a yoghurt.  
   
   
       10 . Use of a pharmaceutical agent according to  claim 1  for the manufacture of an agent for treatment or prophylaxis of cancer.

Join the waitlist — get patent alerts

Track US2007031476A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.